Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Recurso digital |
| Dil: | Çince |
| Baskı/Yayın Bilgisi: |
Zenodo
2026
|
| Konular: | |
| Online Erişim: | https://doi.org/10.5281/zenodo.20115186 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
İçindekiler:
- <p>DESTINY-Breast04 (2022) 確立 trastuzumab deruxtecan 於 HER2-low 第二線;DESTINY-Breast06 (2024) 進一步擴展至 HR+ 內分泌治療後、尚未化療的族群。本文整理 HER2-low 定義、流行病學、IHC 判讀一致性、ILD 監測與 NCCN v3.2026 的新分層。</p><p><strong>線上閱讀:</strong><a href="https://lin.hsiehting.com/posts/2026/her2-low-breast-cancer">https://lin.hsiehting.com/posts/2026/her2-low-breast-cancer</a></p><p><strong>主題:</strong>HER2 低度表現乳癌 (HER2-low breast cancer)</p><p><strong>審稿醫師:</strong>林協霆(MD, 內科專科醫師, 腫瘤內科)<br><strong>審稿日期:</strong>2026-05-11</p>